Filing Details

Accession Number:
0001209191-14-023550
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-03-27 18:36:25
Reporting Period:
2014-03-26
Filing Date:
2014-03-27
Accepted Time:
2014-03-27 18:36:25
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1513818 Versartis Inc. VSAR Pharmaceutical Preparations (2834) 244106690
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1377952 Y Anthony Sun C/O Aisling Capital
888 Seventh Ave., 30Th Floor
New York NY 10106
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-03-26 35,104 $0.00 35,104 No 4 C Indirect See FN
Common Stock Acquisiton 2014-03-26 1,236,715 $0.00 1,271,819 No 4 C Indirect See FN
Common Stock Acquisiton 2014-03-26 128,695 $0.00 1,400,514 No 4 C Indirect See FN
Common Stock Acquisiton 2014-03-26 56,939 $0.00 1,457,453 No 4 C Indirect See FN
Common Stock Acquisiton 2014-03-26 477,115 $0.00 1,934,568 No 4 C Indirect See FN
Common Stock Acquisiton 2014-03-26 60,000 $21.00 1,994,568 No 4 P Indirect See FN
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See FN
No 4 C Indirect See FN
No 4 C Indirect See FN
No 4 C Indirect See FN
No 4 C Indirect See FN
No 4 P Indirect See FN
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B Convertible Preferred Stock Disposition 2014-03-26 403,704 $0.00 35,104 $0.00
Common Stock Series C Convertible Preferred Stock Disposition 2014-03-26 14,222,222 $0.00 1,236,715 $0.00
Common Stock Series D-1 Convertible Preferred Stock Disposition 2014-03-26 1,479,993 $0.00 128,695 $0.00
Common Stock Series D-2 Convertible Preferred Stock Disposition 2014-03-26 654,796 $0.00 56,939 $0.00
Common Stock Series E Convertible Preferred Stock Disposition 2014-03-26 5,486,820 $0.00 477,115 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. In connection with the completion of the Issuer's initial public offering of common Stock, each share of Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, Series D-1 Convertible Preferred Stock, Series D-2 Convertible Preferred Stock and Series E Convertible Preferred Stock automatically converted into Common Stock on a 1-for 11.5 basis.
  2. The reportable securities are owned directly by Aisling Capital III, LP ("Aisling"), and held indirectly by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. Mr. Sun is a member of the investment committee of Aisling. Mr. Sun disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest.
  3. The securities do not have an expiration date. Each share of Series B, Series C, Series D-1, Series D-2 and Series E Convertible Preferred Stock converted automatically into shares of Common Stock in connection with the closing of the Issuer's initial public offering on March 26, 2014. Prior to its conversion into the Issuer's Common Stock, the Series B, Series C, Series D-1, Series D-2 and Series E Convertible Preferred Stock was convertible at any time at the option of the holder.